Project Details

[Return to Previous Page]

Enhancing ELISA Assays for Oligonucleotide Therapeutics: Developing Specialized Assay Buffers to Optimize Pharmacokinetic Assays - Team 2

Company: Triangle Laboratory 2

Major(s):
Primary: BME
Secondary: MATSE

Non-Disclosure Agreement: NO

Intellectual Property: NO

Oligonucleotide therapeutics remains at the forefront of healthcare innovation, rapidly growing as one of key segments in therapeutic research. In the development of these drugs, pharmacokinetic analysis plays a crucial role in understanding their Absorption, Distribution, Metabolism, and Excretion (ADME). Probe-based hybridization ELISA is preferred for pharmacokinetic (PK) assessments due to its high sensitivity and specificity. However, the unique characteristics of oligonucleotides, such as their negative charge, often render standard assay buffers ineffective. This is primarily due to non-specific binding with the oligonucleotide analyte, which can lead to decreased assay specificity and sensitivity. This project is dedicated to the investigation of specialized assay buffers for oligonucleotide-centric ELISA assays. Our goal is to gather scientific knowledge and potentially develop prototype products that enhance the accuracy and reliability of these assays, addressing the specific challenges posed in developing oligonucleotide therapeutics.